摘要
肿瘤学中关于血管靶向治疗中的新目标和治疗方法被不断探索。内因子,一种TGF-β的协同受体,是一个已知靶标。然而,其借助载体RNA干扰技术的沉默还未被研究。因此,在这项研究中,我们为shRAN对抗内因子组合了质粒DNA编码,并将基因电转移作为传送方法来研究其抗肿瘤和血管靶向作用。体外和体内数据提供了内因子沉默的血管靶向作用的证据。内因子沉默的血管靶向作用可被描述为两个单独作用的结果;抗血管生成和血管阻断作用。这个结论首次被体外数据支持;主要通过减少内皮细胞的增殖及其小管形成。在肿瘤细胞不表达内因子的TS/A鼠乳腺癌模型中,肿瘤生长和血管数量的减少被观测到。通过活体显微镜可观测到在背窗室生长的肿瘤中存在肿瘤细胞注入和肿瘤持续生长的位置快速阻断现有的活性血管的现象。这项观测支持了血管阻断和抗血管生长作用。总之,我们的研究结果为内因子作为癌症治疗中有效靶标提供了证据,尤其在联合方案中延长抗肿瘤作用的质粒shRNA传递的进一步发展提供支持。
关键词: 内因子,DNA,腺癌,shRNA。
Current Gene Therapy
Title:Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect
Volume: 15 Issue: 3
Author(s): Tanja Dolinsek, Bostjan Markelc, Masa Bosnjak, Tanja Blagus, Lara Prosen and Simona Kranjc, Monika Stimac, Ursa Lampreht, Gregor Sersa and Maja Cemazar
Affiliation:
关键词: 内因子,DNA,腺癌,shRNA。
摘要: New targets and therapeutic approaches for vascular targeted strategies in oncology are continuously explored. Endoglin, a co-receptor of TGF-β, is a known target, however, its silencing with vector-based RNA interference technology has not been evaluated yet. Therefore, in our study, we assembled plasmid DNA coding for shRNA against endoglin, and used gene electrotransfer as a delivery method to determine its antitumor and vascular targeted effects. In vitro and in vivo data provide evidence of vascular targeted effects of endoglin silencing. The vascular targeted action of endoglin silencing could be described as a result of two separated effect; antiangiogenic and vascular disrupting effect. This was first supported by in vitro data; predominantly by reduction of proliferation and tube formation of endothelial cells. In the TS/A murine mammary carcinoma model, in which the tumor cells do not express endoglin, reduced tumor growth and number of vessels were observed. Quick destruction of existing activated blood vessels at the site of tumor cells’ injection and sustained growth of tumors afterwards was observed in tumors that were growing in dorsal window chamber by intravital microscopy. This observation supports both vascular disrupting and antiangiogenic action. In conclusion, the results of our study provide evidence of endoglin as a valid target for cancer therapy and support further development of plasmid shRNA delivery, which have prolonged antitumor effect, especially in combined schedules.
Export Options
About this article
Cite this article as:
Tanja Dolinsek, Bostjan Markelc, Masa Bosnjak, Tanja Blagus, Lara Prosen and Simona Kranjc, Monika Stimac, Ursa Lampreht, Gregor Sersa and Maja Cemazar , Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect, Current Gene Therapy 2015; 15 (3) . https://dx.doi.org/10.2174/1566523215666150126115501
DOI https://dx.doi.org/10.2174/1566523215666150126115501 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Albumin-Based Nanodevices as Drug Carriers
Current Pharmaceutical Design MicroRNAs as Main Players in the Pathogenesis of Chronic Lymphocytic Leukemia
MicroRNA Progress of Stimuli-Responsive Nanoscale Metal Organic Frameworks as Controlled Drug Delivery Systems
Current Drug Delivery Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Nanomedicine for Cancer Therapy Using Autophagy: An Overview
Current Topics in Medicinal Chemistry Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and Metastasis
Current Pharmaceutical Design Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) The Association of Chemotherapy and Radiotherapy: Biological Rationale
Current Drug Therapy Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
Current Cancer Drug Targets Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Multicomponent Reactions in Antimitotic Drug Discovery
Current Topics in Medicinal Chemistry The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Advances in Hyaluronic Acid-Based Drug Delivery Systems
Current Drug Targets Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics